StockData
Castle Biosciences Inc logo

Castle Biosciences Inc (CSTL) stock

CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/304% below fair value
$32.98+0.23 (+0.70%)

Close on Nov 17, 2026Market cap $1.01BP/E –Yield 0.00%

Castle Biosciences r&d expenses

Research and development expenses are spending on new products and technology.

Castle Biosciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $58.29M, up 16.3% year over year. For fiscal 2025 it was $51.85M, down 0.4% from the year before. The highest annual figure on record is $53.62M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$51.85M-0.4%
FY2024Dec 31, 2024$52.04M-2.9%
FY2023Dec 31, 2023$53.62M+19.4%
FY2022Dec 31, 2022$44.90M+51.5%
FY2021Dec 31, 2021$29.65M+123.6%
FY2020Dec 31, 2020$13.26M+79.5%
FY2019Dec 31, 2019$7.39M+52.1%
FY2018Dec 31, 2018$4.85M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$15.81M+22.0%
Q2 FY2026Jun 30, 2026$14.54M+13.7%
Q1 FY2026Mar 31, 2026$14.43M+14.6%
Q4 FY2025Dec 31, 2025$13.52M+14.8%
Q3 FY2025Sep 30, 2025$12.96M+5.2%
Q2 FY2025Jun 30, 2025$12.79M-9.5%
Q1 FY2025Mar 31, 2025$12.59M-8.8%
Q4 FY2024Dec 31, 2024$11.77M-9.4%
Q3 FY2024Sep 30, 2024$12.32M-4.6%
Q2 FY2024Jun 30, 2024$14.14M+6.2%
Q1 FY2024Mar 31, 2024$13.81M-4.1%
Q4 FY2023Dec 31, 2023$12.99M+14.9%
Q3 FY2023Sep 30, 2023$12.92M+18.5%
Q2 FY2023Jun 30, 2023$13.31M+11.6%
Q1 FY2023Mar 31, 2023$14.39M+33.8%
Q4 FY2022Dec 31, 2022$11.31M+19.7%
Q3 FY2022Sep 30, 2022$10.91M+45.4%
Q2 FY2022Jun 30, 2022$11.93M+75.6%
Q1 FY2022Mar 31, 2022$10.76M+82.1%
Q4 FY2021Dec 31, 2021$9.45M+106.2%
Q3 FY2021Sep 30, 2021$7.50M+145.3%
Q2 FY2021Jun 30, 2021$6.79M+151.2%
Q1 FY2021Mar 31, 2021$5.91M+102.8%
Q4 FY2020Dec 31, 2020$4.58M+45.0%
Q3 FY2020Sep 30, 2020$3.06M+101.8%
Q2 FY2020Jun 30, 2020$2.70M+105.3%
Q1 FY2020Mar 31, 2020$2.91M+109.0%
Q4 FY2019Dec 31, 2019$3.16M+177.6%
Q3 FY2019Sep 30, 2019$1.52M+17.1%
Q2 FY2019Jun 30, 2019$1.32M+13.6%
Q1 FY2019Mar 31, 2019$1.39M–
Q4 FY2018Dec 31, 2018$1.14M–
Q3 FY2018Sep 30, 2018$1.29M–
Q2 FY2018Jun 30, 2018$1.16M–

More Castle Biosciences figures

See a number that looks wrong?